Genazzani Andrea R, Schneider Hermann P G, Panay Nick, Nijland Esme A
Department of Gynecology and Obstetrics, University of Pisa, Pisa, Italy.
Gynecol Endocrinol. 2006 Jul;22(7):369-75. doi: 10.1080/09513590600842463.
To identify and describe current women's thoughts about the menopause, hormone treatment (HT) and perceptions about breast cancer.
Between December 2004 and January 2005, 4201 postmenopausal women in seven European countries were interviewed via a standardized computer-aided telephone interview protocol.
Almost all women reported to have experienced climacteric symptoms, and 63% of the women rated them as being severe. Only 52% of women were aware of the benefits of HT for relief of climacteric symptoms. Although 84% felt that severe symptoms should be treated, only 40% had used HT at some point in time. Thirty-four percent of the women preferring treatment with natural products did so because of the risk of breast cancer associated with HT. HT was recognized by 59% of the women as one of the most important contributors to an increased breast cancer risk. Most women received their information about HT and breast cancer risk from the media.
This European survey reveals that the majority of women experience climacteric symptoms but that their decision whether or not to use HT is highly dependent on their concern about breast cancer risk. An increase in knowledge of the benefits and risks of HT is required for women to make appropriate decisions about hormone use.
识别并描述当前女性对于更年期、激素治疗(HT)以及乳腺癌的看法。
在2004年12月至2005年1月期间,通过标准化的计算机辅助电话访谈协议,对七个欧洲国家的4201名绝经后女性进行了访谈。
几乎所有女性都报告经历过更年期症状,63%的女性认为这些症状严重。只有52%的女性知晓HT对缓解更年期症状的益处。尽管84%的女性认为严重症状应接受治疗,但只有40%的女性曾在某个时间点使用过HT。34%倾向于使用天然产品进行治疗的女性是因为担心HT与乳腺癌相关的风险。59%的女性认为HT是导致乳腺癌风险增加的最重要因素之一。大多数女性关于HT和乳腺癌风险的信息来自媒体。
这项欧洲调查显示,大多数女性经历过更年期症状,但她们是否使用HT的决定高度取决于其对乳腺癌风险的担忧。为使女性能够就激素使用做出恰当决定,需要增加她们对HT益处和风险的了解。